Search

Influenza B virus (IBV) contributes to substantial influenza-mediated morbidity and mortality, particularly among children. Similar to influenza A viruses (IAV), the hemagglutinin (HA) and neuraminidase (NA) of IBV undergo antigenic drift, necessitating regular reformulation of seasonal influenza vaccines. NA inhibitors, such as oseltamivir, have reduced activity and clinical efficacy against IBV, while M2 channel inhibitors are only effective against IAV, highlighting the need for improved vaccine and therapeutics for the treatment of seasonal IBV infections. We have previously described a potent human monoclonal antibody (hMAb), 1092D4, that is specific for IBV NA and neutralizes a broad range of IBVs. The anti-viral activity of MAbs can include direct mechanisms such as through neutralization and/or Fc-mediated effector functions that are dependent on accessory cells expressing Fc receptors and that could be impacted by potential host-dependent variability. To discern if the in vivo efficacy of 1092D4 was dependent on Fc-effector function, 1092D4 hMAb with reduced ability to bind to Fc receptors (1092D4–LALAPG) was generated and tested. 1092D4–LALAPG had comparable in vitro binding, neutralization, and inhibition of NA activity to 1092D4. 1092D4–LALAPG was effective at protecting against a lethal challenge of IBV in mice. These results suggest that hMAb 1092D4 in vivo activity is minimally dependent on Fc-effector functions, a characteristic that may extend to other hMAbs that have potent NA inhibition activity. [ABSTRACT FROM AUTHOR]

The most potent and broad HIV envelope (Env)-specific antibodies often when reverted to their inferred germline versions representing the naive B cell receptor, fail to bind Env, suggesting that the initial responding B cell population not only exclusively comprises a naive population, but also a pre-existing cross-reactive antigen-experienced B cell pool that expands following Env exposure. Previously we isolated gp120-reactive monoclonal antibodies (mAbs) from participants in HVTN 105, an HIV vaccine trial. Using deep sequencing, focused on immunoglobulin G (IgG), IgA, and IgM, VH-lineage tracking, we identified four of these mAb lineages in pre-immune peripheral blood. We also looked through the ∼7 month postvaccination bone marrow, and interestingly, several of these lineages that were found in prevaccination blood were still persistent in the postvaccination bone marrow, including the CD138+ long-lived plasma cell compartment. The majority of the pre-immune lineage members included IgM, however, IgG and IgA members were also prevalent and exhibited somatic hypermutation. These results suggest that vaccine-induced gp120-specific antibody lineages originate from both naive and cross-reactive memory B cells. ClinicalTrials.gov NCT02207920 [ABSTRACT FROM AUTHOR]

Abstract: Cyclosporin-A (CYP-A) is a widely used immunosuppressive drug. Yet, information on the long-term impact of embryonic exposure is relatively scarce. The effects of CYP-A on reproductive and immunologic parameters in CD strain female offspring exposed in utero at doses of 0, 0.2, 2, 10, or 20mg/kg/day (from gestational day 6 to 21) were compared against identically dosed CD adult rats. Embryotoxicity was seen at the two highest doses. CYP-A was acutely immunotoxic in adults (tested at 20mg/kg/day dose) but with minimum long-term effects. In contrast, the offspring experienced relatively persistent alterations. CYP-A exposure increased ano-genital distance in the neonates. In the 5-week-old offspring, the delayed type hypersensitivity (DTH) response and splenic B cell number (determined by flow cytometry) were both decreased at the 2mg dose level. IL-4 level was reduced and blood monocytes were increased at both exposure doses. All other parameters were unchanged. In the adult offspring (13-week-old), no difference was seen in either the DTH response or B cell ratios, but IL-4 level was increased at 2mg/kg/day, and anti-KLH IgG titer decreased at both doses. In exposed non-pregnant adults, changes were minimal following a 13-week recovery period. Blood neutrophils were increased at all doses of the drug and flow cytometry data suggested some perturbation in CD4+CD8+ cells, macrophages, and B-cells. All other parameters were unchanged. In conclusion, the adult rodent immune system largely recovers from CYP-A exposure given sufficient time. However, embryonic exposure appears to produce a series of immune perturbations including functional impairment during postnatal maturation. [Copyright &y& Elsevier]

Di-(2-ethylhexyl)phthalate (DEHP) helps provide flexibility to plastic products including food containers and medical IV devices. Age-based sensitivity to DEHP-induced immunotoxicity was compared in female CD strain rats following administration for 16 consecutive days in utero vs. adult exposure. Pregnant and non-pregnant rats received 0, 37.5, 75, 150, or 300 mg/kg/day of DEHP in soybean oil daily by oral gavage. In pregnant animals, this corresponded to days 6–21 of gestation. In exposed offspring, anogenital distance (AGD) was measured at one and three weeks of age. For a subset of offspring, immune assessment was conducted at 5 weeks of age following KLH immunization at 3 and 4 weeks. KLH immunizations occurred in remaining offspring at 11 and 12 weeks with immune assessment at 13 weeks. Nonpregnant adults were immunized concurrently with adult offspring and underwent immune assessment 13 weeks post-DEHP exposure. Litter size, sex ratio, and 1-week body weights were unaffected by treatment. However, AGD was altered at both ages assessed. Three-week (but not 5-week) body weights were elevated in exposed offspring. Immune organ weights, thymus histology, antibody levels (IgG and IgE), DTH reaction to KLH, total and differential leukocyte counts, ex vivo cytokine production (IL-2, -4, -10, -12, interferon-gamma), as well as TNF-alpha and nitric oxide production by macrophages were not altered by treatment at any age. Flow cytometry analysis of splenocytes showed no differences during the juvenile assessment. In conclusion, in utero exposure of female rats to DEHP alters some developmental parameters (i.e., AGD) but has no persistent effect on the immune system based on the assessment parameters. Adult female rats also had no detectable immune alteration following similar exposures. [ABSTRACT FROM AUTHOR]